Septerna, INC S-1 registration statements

Septerna, Inc. is increasing the number of shares offered in its initial public offering by 830,556 shares, including an underwriter option, through a Form S-1 filing with the SEC.

Septerna, a clinical-stage biotech firm, is seeking to raise $250 million through an initial public offering to further the development of its oral small molecule GPCR-targeted drug pipeline.

Septerna, Inc. files an amended S-1/A form detailing changes to its bylaws, particularly regarding stockholder meetings and director nominations, as it prepares for its initial public offering.

Septerna, Inc. files an S-1 registration statement, detailing an amended investors' rights agreement in preparation for its initial public offering.